Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes

Journal of Psychiatric Research

Volumn 44, Issue 9, 2010, Pages 561-565

  Fernandes, Brisa Simões ^a,b   Gama, Clarissa Severino ^a,b   Walz, Julio C ^a,b   Ceresér, Keila Maria ^a,b   Fries, Gabriel Rodrigo ^a,b,c   Colpo, Gabriela ^a   Aguiar, Bianca ^a   Pfaffenseller, Bianca ^a   Kauer Sant'Anna, Marcia ^a,b   Kapczinski, Flavio ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Universidade Federal do Rio Grande do Sul ^*  (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Biological marker; Bipolar disorder; Depression; Mania; Mood stabilizers; NT 3

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTROPHIN 3;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG USE; FEMALE; HUMAN; MALE; MANIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROTROPHIN 3;

EID: 77953288705     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.11.020     Document Type: Article

References (22)

1. Agerman K., Ernfors P. Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo. Neuroreport 2003, 14(17):2183-2187.
2. APA. Diagnostic and statistical manual of mental disorders. Washington, DC; 2000.
3. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters 2006, 398(3):215-219.
4. de Oliveira G.S., Cereser K.M., Fernandes B.S., Kauer-Sant'Anna M., Fries G.R., Stertz L., et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. Journal of Psychiatric Research 2009, 43(14):1171-1174.
5. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biological Psychiatry 2006, 59(12):1116-1127.
6. Fernandes B.S., Gama C.S., Kauer-Sant'Anna M., Lobato M.I., Belmonte-de-Abreu P., Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. Journal of Psychiatric Research 2009, 43(15):1200-1204.
7. Fernandes B., Gama C.S., Massuda R., Torres M., Camargo D., Kunz M., et al. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): a pilot study in drug resistant depressed patients. Neuroscience Letters 2009, 453(3):195-198.
8. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neuroscience Letters 2007, 420(1):45-48.
9. Giehl K.M., Rohrig S., Bonatz H., Gutjahr M., Leiner B., Bartke I., et al. Endogenous brain-derived neurotrophic factor and neurotrophin-3 antagonistically regulate survival of axotomized corticospinal neurons in vivo. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2001, 21(10):3492-3502.
10. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960, 23:56-62.
11. Kapczinski F., Fernandes B.S., Kauer-Sant'Anna M., Gama C.S., Yatham L., Berk M. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica 2009, 21(6):272-274.
12. Kapczinski F., Teixeira A.L., Magalhaes P.V.S., Kauer-Sant'Anna M., Klamt F., Pasquali M.A., et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Molecular Psychiatry 2009, 10.1038/mp.2009.11.
13. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R., Berk M. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Review of Neurotherapeutics 2008, 8(7):1101-1113.
14. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews 2008, 32(4):675-692.
15. Kato A., Fukazawa Y., Ozawa F., Inokuchi K., Sugiyama H. Activation of ERK cascade promotes accumulation of Vesl-1S/Homer-1a immunoreactivity at synapses. Brain Research. Molecular Brain Research 2003, 118(1-2):33-44.
16. Pan W., Banks W.A., Kastin A.J. Permeability of the blood-brain barrier to neurotrophins. Brain Research 1998, 788(1-2):87-94.
17. Schutte A., Yan Q., Mestres P., Giehl K.M. The endogenous survival promotion of axotomized rat corticospinal neurons by brain-derived neurotrophic factor is mediated via paracrine, rather than autocrine mechanisms. Neuroscience Letters 2000, 290(3):185-188.
18. Tramontina J.F., Andreazza A.C., Kauer-Sant'anna M., Stertz L., Goi J., Chiarani F., et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neuroscience Letters 2009, 452(2):111-113.
19. Walz J.C., Andreazza A.C., Frey B.N., Cacilhas A.A., Cereser K.M., Cunha A.B., et al. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neuroscience Letters 2007, 415(1):87-89.
20. Walz J.C., Frey B.N., Andreazza A.C., Cereser K.M., Cacilhas A.A., Valvassori S.S., et al. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. Journal of Psychiatric Research 2008, 42(5):416-421.
21. Yatham L.N., Kennedy S.H., Schaffer A., Parikh S.V., Beaulieu S., O'Donovan C., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disorders 2009, 11(3):225-255.
22. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. The British Journal of Psychiatry: The Journal of Mental Science 1978, 133:429-435.